but little improvement has been achieved in the outcomes of patients with advanced or metastatic disease. Almost 90% of those patients eventually succumb to their cancer.
INTRODUCTION
Urothelial cancer of the bladder (bc) is the 4th most common cancer in American men and the 9th most common in women, leading to 14,330 new deaths annually 1 . Although most newly diagnosed tumours are still superficial, up to 25% will initially present with muscle invasion, half of which will be metastatic disease. Furthermore, of tumours that are initially superficial, 20% will progress despite intravesical chemo-and immunotherapy and will become muscle-invasive 2, 3 . Conventional chemotherapy in the neoadjuvant setting-and more particularly, platinum-based regimens-has shown promising results in the management of locally invasive tumours,
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Overall, although single-agent therapy produced some promising responses in these tumours, the generally disappointing survival data have set researchers to investigating combinations of these potentially beneficial agents in the hope of improving outcomes.
Combination Chemotherapy
The so-called modern era in the management of advanced bc probably started when two landmark cisplatin-based chemotherapy studies set the tone for future management of these tumours 12, 13 . Before those reports, life expectancy without chemotherapy for this subset of patients was about 6 months 14, 15 .
In the first of the two trials (Northern California Oncology Group), a regimen consisting of cisplatin, methotrexate, and vinblastine was used, achieving an or of 56% and a complete response (cr) rate of 28%, with a median overall survival (os) of 8 months 12 . The second trial used the m vac regimen to greater success, with or and cr rates of approximately 70% and 35% respectively, and an improved median os of 13 months 13 . Two prospective trials were therefore initiated to validate the role of m vac in this patient population 16, 17 .
In the first prospective trial, the European Cooperative Oncology Group (ecog) randomized 246 patients to receive either cisplatin alone or mvac, and with the latter, they observed a significantly higher or (12% vs. 39%, p < 0.0001) and mds (8 months vs. 12.5 months) 16 . However, on long-term followup, the survival benefit associated with mvac was only 4.3%, and only 3.7% of patients experienced disease-free survival at 6 years 4 . The second prospective trial compared mvac with a regimen consisting of cisplatin, cyclophosphamide, and doxorubicin, and similarly showed that mvac resulted in a higher or (65% vs. 46%, p < 0.05) and os (62.6 weeks vs. 40.4 weeks) 17 .
In an effort to improve outcomes and lower toxicity with mvac therapy, the European Organisation for Research and Treatment of Cancer investigated the potential role of high-dose mvac (hd-mvac), which consisted of rapid 2-week cycles (instead of the standard 4 weeks). A total of 246 patients were randomized to receive either standard mvac or hd-mvac. Although the or and os rates were similar, progression-free survival (pfs) was significantly improved (9.5 months vs. 8.1 months, p = 0.037) and toxicity was decreased in patients treated with hd-mvac 18 .
2.2.1
Cisplatin-Based Doublets Other single agents that had shown antitumour activity in bc were examined in combination with cisplatin 19 . Most notably, 220 patients were randomized to receive either mvac or a regimen of cisplatin and docetaxel. Results were unflattering to the cisplatindocetaxel doublet, and the mvac group continued to display a better relative risk (rr: 54.2% vs. 37.4%, p = 0.017) and mds (14.2 months vs. 9.3 months, p = 0.026) 20 . However, in three phase ii trials, a gemcitabine-cisplatin (gc) regimen showed activity comparable to that for mvac 19 . Those findings were subsequently assessed in a randomized phase iii study of 405 patients with advanced bc who received either mvac or gc 21 . The latter study did not achieve its initial goal of showing superiority of gc, but the 2 groups displayed similar rr (49% with mvac vs. 46% with gc), mds (14.8 months with mvac vs. 13.8 months with gc), and pfs (7.4 months for both). Importantly, the gc group experienced significantly fewer side effects. With longer 5-year follow-up, similar survival was maintained between the groups, indicating that gc shows therapeutic non-inferiority together with less toxicity as compared with mvac. As such, gc has become a standard of care for patients with metastatic bc 22 . To date, no phase iii trials have compared hdmvac and gc.
Although cisplatin-based therapy had been shown to offer improved results in patients with advanced bc, its nephrotoxic properties continued to make it undesirable, especially in this subset of patients, who often have compromised renal function. And so carboplatin, an alkylating agent with properties similar to, but less nephrotoxic than, those of cisplatin, was investigated for its potential alternative role. Initial reports from phase ii trials with paclitaxel and carboplatin were encouraging in patients deemed unfit for cisplatin, with ors ranging from 21% to 63% and fewer associated toxicities [23] [24] [25] . Subsequently, a phase iii ecog trial compared mvac with a regimen consisting of carboplatin and paclitaxel in patients with advanced bc. Preliminary results were promising, showing similar mds (13.8 months for carboplatin-paclitaxel vs. 15.4 months for mvac, p = 0.65), but patient accrual was too low (n = 85). The study was closed early, and no conclusions could be made 26 . Similarly, a carboplatin regimen was investigated alongside gemcitabine in phase ii trials that did not exclude patients fit to receive cisplatin, resulting in ors of 56% and 59% and a median os of only 10 months [27] [28] [29] . In a phase ii randomized trial of gc versus gemcitabine with carboplatin, better response rates were observed with gc (66% vs. 35%) without significant differences in toxicity profile 30 . Based on the foregoing findings, it became evident that carboplatin is inferior to cisplatin. Carboplatin is currently reserved only for patients who are ineligible to receive cisplatin.
2.2.2
Platinum-Free Doublets In an additional effort to avoid cisplatin-related toxicities, trials were conducted using platinum-free agents. One such regimen consisted of paclitaxel and gemcitabine; it showed response rates of 40%-60% 31 . In a phase ii trial of the same regimen in a weekly schedule, a cr of 42% (mds: 11.9 months) was achieved, but the excitement with these results was damped by the high level of associated pulmonary
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Current OnCOlOgy-VOlume 18, number 1 toxicity (including 1 death) 32 . Furthermore, a regimen consisting of docetaxel and gemcitabine showed promising response rates of 30%-50% and median os times of 13-15 months in phase ii trials [33] [34] [35] . Finally, gemcitabine was also combined with pemetrexed in phase ii trials, resulting in modest response rates of about 25%, but with increased toxicity 36 .
2.2.3
Doublets Compared with Triplets Finally, to improve on outcomes obtained with dual therapy, attempts were made to combine 3 or more agents. In the first study, consisting of a regimen of ifosfamide, paclitaxel, and cisplatin, 23% of assessable patients achieved a cr with a mds of 20 months 37 . Based on those results, a phase ii study investigated the benefit of dose-dense sequential chemotherapy with doxorubicin and gemcitabine followed by ifosfamide-paclitaxel-cisplatin, achieving a rr of 73% and a mds of 24 months 38 . After that success, paclitaxel was incorporated into a regimen with gemcitabine and cisplatin (pgc) in a phase ii trial that showed an excellent or of 78% 31 . That result led to the largest-to-date randomized trial in advanced bc, which compared gc with pgc. The pgc combination was found to be associated with a significantly better cr rate (10% vs. 15%, p = 0.02), but no significant improvement in pfs or os was demonstrated 39 . A phase ii trial with a regimen of gemcitabine, paclitaxel, and carboplatin in 49 patients resulted in a cr of 32% and a mds of 14.7 months 40 , but in another phase ii trial using the same regimen, the reported cr was only 12%, and the mds, 11 months 41 .
At the present time, data from randomized phase iii trials suggest that systemic cisplatin-based combination chemotherapy (mvac or gc) remains the only current modality to have shown improved survival in patients with advanced bc. Accordingly, both the National Comprehensive Cancer Network and the European Society of Medical Oncology recommend either mvac or gc as first-line treatment in those patients 42, 43 .
PROGNOSTIC FACTORS
In the long follow-up of the ecog study comparing mvac with cisplatin, the Karnofsky performance status (kps ≥80 vs. kps <80; p = 0.000011) was found to be an independent predictor of survival. Furthermore, the presence of liver or bone metastases was also a predictor of poor outcome (p = 0.0022 and p = 0.0032 respectively) 4 . Later analysis further established that those two prognostic factors-kps less than 80% and visceral (lung, liver, bone) metastasiswere both predictive of response and survival 44 . Accordingly, three risk categories were established depending on the number of risk factors (0, 1, or 2). Median survival times were 33 months, 13 months, and 9 months respectively for those risk factors (p = 0.0001) 44 . Similar results were also reported in the long-term follow-up of the mvac and gc comparative study and in a phase i/ii trial of paclitaxel, cisplatin, and gemcitabine 22, 45 .
SECOND-LINE THERAPY
Patients who recur after first-line therapy have a very poor prognosis. Because of the lack of randomized trials showing benefit for any therapy over supportive care, most evidence comes from small phase ii trials of single agents, combinations of agents, and new targeted therapies.
Single-Agent Second-Line Therapy
Multiple single agents have been assessed for their benefit in patients who relapse despite first-line therapy ( Table i) . In examining older agents, only ifosfamide seemed to have shown any promise in this subset of patients. In a phase ii trial, 56 cisplatinpretreated patients received ifosfamide and achieved an or of 20%, with a mds of 5.3 months 49 .
Paclitaxel was investigated in three small phase ii trials. In a cohort of 31 pretreated patients, or and pr rates of 10% were observed, with a mds of 7.2 months 56 . However, in the other two trials, lower response rates of 5%-7% were achieved, with a mds of 6.5 months 47, 58 . Similarly, docetaxel was investigated in 31 cisplatin-refractory patients. The result was a better or rate of 13% and a mds of 9 months. However, 60% of the patients developed myelosuppression, and dose reduction was required 9 .
An evaluation by ecog of epothilone B in a phase ii trial involving 45 patients with recurrence after cisplatin-or carboplatin-based chemotherapy showed an or of 12% and a m ds of 8 months; however, because of high toxicity and 1 related fatality, the drug was dropped from further evaluation 62 . Similarly, pyrazoloacridine was investigated in 14 patients with chemo-refractory advanced bc. No responses were observed (0%), and the associated toxicities were elevated; further trials were therefore discontinued 53 .
Gemcitabine was also studied for its potential role in previously treated patients. As in first-line trials, it was associated with a wide spectrum of response and survival outcomes depending on the various scheduling and dosing regimens used 11, 66, 67 . In a phase i study of patients previously treated with mvac, an or rate of 27% was achieved when various doses of gemcitabine were used 68 . However, in two phase ii trials of platinum-refractory patients receiving 1250 mg/m 2 in 4-and 3-week cycles, the or rates were 23% and 11%, with mds durations of 5 months and 8.7 months respectively 50, 54 .
Piritrexim, a second-generation oral antimetabolite, has resulted in ors ranging between 7% and 23%, but more importantly, considerable toxicity 46, 55 . Those results have been further confirmed by another phase ii trial in 23 previously treated patients, among e28 whom only 2 demonstrated stable disease after 2-4 cycles; further enrolment was therefore halted 69 . Another anti-folate, pemetrexed, was investigated in a phase ii trial in 47 patients who had a performance status of 0 or 1 and adequate organ function, and who had been treated with one prior chemotherapy regimen 59 . Of the 47 patients, 13 (27.7%) achieved an or (6% cr, 21% pr), with a median duration of response of 5 months and a mds of 9.6 months. Importantly, the drug was well tolerated. The most serious toxicities were grades 3 and 4 hematologic events in 14.9% and 6.4% of patients respectively. However, in another phase ii trial of the same drug, only 1 of 12 evaluable patients attained a response (or: 8%), and the trial was therefore halted 63 .
The third-generation semi-synthetic vinca alkaloid vinflunine (vfl) has been assessed as second-line therapy in two phase ii trials. In the first of those trials, 51 patients completed the study, attaining an or rate of 18% and a pfs of 3 months. Toxicity consisted mainly of grade 3 or 4 neutropenia (67%) and febrile neutropenia (5%) 60 . The second trial included 175 patients with platinum-refractory bc, and in 150 patients, the or rate was 15%, with a mds of 8.2 months and a more favourable toxicity profile 65 . Based on those results, a large phase iii trial randomized 370 patients to receive either vfl with bsc or bsc alone 64 . The study was limited to platinum-pretreated patients with ecog performance scores of 0 or 1. In the vfl arm, toxicities included grades 3 and 4 neutropenia (50% of patients), febrile neutropenia (6%), fatigue (19%), and constipation (16%); 1 toxic death occurred. In the eligible population, the median os was prolonged in the vfl group (6.9 months vs. 4.3 months, p = 0.04). Importantly, by intention-to-treat analysis, the difference was not statistically significant (p = 0.29). On adjusted multivariate analysis, addition of vfl was an independent prognostic factor for improved os (p = 0.036), reducing the risk of death by 23% (hazard ratio: 0.77) 64 . Currently, an ongoing phase iii clinical trial is randomizing cisplatin-ineligible patients with advanced bc to vfl and gemcitabine or to placebo and gemcitabine (search for NCT00389155 at www. clinicaltrials.gov/ct2/search).
Multi-Agent Second-Line Therapy
Multidrug combinations have been thoroughly investigated as second-line therapy for bc and have generally yielded better response rates, but not necessarily better survival outcomes, and often higher toxicity (Table ii) . In patients progressing on gc or relapsing within 6 to 12 months and still eligible for cisplatin therapy, recent data have shown that a second-line regimen of mvac can offer acceptable outcomes, with an or of 30% and a mds of 10.9 months 87 . The most extensively studied second-line combination regimen is paclitaxel and gemcitabine. As with other second-line treatments, large discrepancies can easily be noted when dosing and scheduling regimens are modified. In an early phase ii trial in which 21-or 14-day cycles with various concentrations of the drugs were used in chemo-resistant patients, the or was 44% for the entire population, but the mds was higher with the longer cycle (13 months vs. 9 months) 81 . In two more recent phase ii studies in platinum-refractory patients, an or of 33% and a mds of 11.3 months were achieved with 180 mg/m 2 paclitaxel on day 1 and 1000 mg/m 2 gemcitabine on days 1, 8, and 15 every 28 days; and an or of 30% and a mds of 11.5 months were achieved with a lesser dose of paclitaxel (150 mg/m 2 ) and a higher dose of gemcitabine (2500 mg/m 2 ) at a shorter interval of every 2 or 3 weeks 85 . In a phase iii trial in chemorefractory patients, a temporary 6-cycle course of paclitaxel and gemcitabine (3-week schedule) was compared with a maintenance treatment until progression, and results showed an or of 50% in the latter group, but no survival difference between the two arms 84 .
Finally, and only recently, interest has arisen in metronomic therapy, which consists of the use of cytostatics administered at frequent intervals and which has been shown to offer benefit for patients with other cancers [88] [89] [90] [91] . Spurred by those results, a phase i/ii study of paclitaxel in combination with oral cyclophosphamide was conducted in 44 patients pre-treated with gc. The pr and or rates of 31% were attained with a mds of 8 months, and the regimen was well tolerated 88 . Similarly, a phase ii trial in which 22 mvac-pre-treated patients received weekly paclitaxel and carboplatin found an or of 36% and a mds of 7.9 months; however, 1 treatment-related death occurred 92 .
In the absence of conclusive data, no definitive recommendations can be put forth with regard to second-line systemic therapy. However, some evidence supports the use of cisplatin-based second-line therapy in patients who previously responded to firstline cisplatin-based therapy (more than a 6-month duration from last treatment to progression) and who are considered platinum-sensitive.
QUALITY OF LIFE WITH CHEMOTHERAPY FOR ADVANCED OR METASTATIC BLADDER CANCER
Historically, quality of life (qol) in patients receiving chemotherapy as compared with bsc has not been 
TARGETED THERAPY
Advances in molecular research are helping to develop reliable biomarkers that may allow physicians to more accurately use targeted, pathwaybased therapies. In a phase ii trial of bortezomib in patients refractory to cisplatin, 70% progressed, with a mds of 5.7 months 93 . In another trial, 14 previously treated patients received vorinostat, none achieved a response, the median os was 2.1 months, and associated toxicities were elevated 94 . Furthermore, in a phase ii trial of 27 patients receiving sorafenib, the or rate was nil, and the median pfs was 2.2 months 95 . Similarly, in a phase ii trial in 45 previously treated patients receiving sunitinib, an or rate of 7.3% was achieved, but the associated toxicities were major 96 . Finally, bevacizumab was associated with a good response in the case report of a 78-year-old man with metastatic bc who, at last follow-up, had received 24 months of bevacizumab with minimal toxicity 97 . This result has spurred interest in bevacizumab, and future studies are awaited.
ONGOING CLINICAL TRIALS FOR ADVANCED BLADDER CANCER
A review of current clinical trials shows that multiple therapeutic regimens are being investigated as first-and second-line regimens (search using "advanced bladder cancer" at www.clinicaltrials. gov/ct2/search). In chemotherapy-naïve patients, sorafenib, sunitinib, tipifarnib, and combination therapies such as paclitaxel-cisplatin-gemcitabine, paclitaxel-carboplatin-gemcitabine, cisplatin-gemcitabine-bevacizumab, carboplatingemcitabine-bevacizumab, and gemcitabinecarboplatin-sorafenib are being offered in phase ii trials. Additionally, three phase i i i trials are randomizing patients to v fl -gemcitabine or to placebo-gemcitabine; gemcitabine-cisplatin-bevacizumab or gemcitabine-cisplatin-placebo; and cisplatin-larotaxel or gc (search for NCT00389155, NCT00234494, and NCT00625664 at www.clinical trials.gov/ct2/search). However, the latter study was prematurely closed because of two other negative larotaxel studies. With regard to second-line therapy, ongoing phase ii trials are investigating agents such as sunitinib, pralatrexate, romidepsin, gefitinib, irinotecan, paclitaxel, oral rubitecan, AZD 8477, everolimus, and the combinations lonafarnib-gemcitabine and sorafenib-bevacizumab (search using "advanced bladder cancer second-line therapy" at www.clinicaltrials.gov/ct2/search).
SURGERY FOR ADVANCED DISEASE
Current evidence suggests that, although advanced bc is an aggressive disease that tends to spread rapidly, surgical consolidation after a major and durable response to systemic chemotherapy is beneficial in a highly select group of patients. This topic is, however, beyond the scope of the present review and will not be addressed here. We recommend that readers refer to our article that covers this subject in detail 98 .
SUMMARY
A plateau has been reached in the management of patients with advanced bc, because the addition of cytotoxic, high-dose, and doublet and triplet therapies have failed to significantly improve outcomes. Currently, the established standard of care for firstline therapy is gc and m vac in platinum-eligible patients. Carboplatin-paclitaxel or gemcitabinecarboplatin are being considered for those unable to receive cisplatin. In patients who recur or who are refractory to first-line therapy, response rates and outcomes are grim, and to date, no secondline therapy has been clearly established. As such, most practice relies on small phase ii studies, case reports, or consensus opinions. In patients previously treated with first-line cisplatin-based therapy and considered to be platinum-sensitive, with more than a 6-month duration from last treatment to progression, the same cisplatin regimen remains a viable option. Novel targeted therapies are sorely needed to further improve the delivery and efficacy of chemotherapy.
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